{"id":"W3036940367","doi":"10.1182/bloodadvances.2019001367","title":"KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Leukemia and Lymphoma Society","keywords":"Brentuximab vedotin; Pembrolizumab; Medicine; Internal medicine; Oncology; Hodgkin lymphoma; Lymphoma; Cancer research; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004902459,0.0002633323,0.0006269829,0.00008626623,0.00002686974,0.0000171936,0.0001252702,0.0001110716,0.0001952111],"category_scores_gemma":[0.0001119362,0.0002094202,0.0002156058,0.0003191789,0.00009650872,0.0001602248,0.00007442995,0.00008956242,0.00008528898],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006777549,"about_ca_system_score_gemma":0.0001449704,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003402769,"about_ca_topic_score_gemma":0.000110047,"domain_scores_codex":[0.9983214,0.00005075775,0.0004304679,0.0004623422,0.0003850126,0.0003500268],"domain_scores_gemma":[0.9992288,0.00009437644,0.0001211472,0.0002683687,0.00005989415,0.0002273928],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00534912,0.004789825,0.9212595,0.000571046,0.0004016244,0.001322452,0.001324211,0.00001782974,0.002452607,0.0008260727,0.002063016,0.05962272],"study_design_scores_gemma":[0.09462693,0.003273754,0.7582609,0.0007220635,0.0007694479,0.0001175207,0.0007378117,0.0001400409,0.05413438,0.0002654872,0.08635786,0.0005937626],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888384,0.00454029,0.00001119134,0.00464539,0.0001347501,0.0004067369,0.00004168974,0.00005880458,0.001322712],"genre_scores_gemma":[0.9969559,0.0003715664,0.001474708,0.0006928997,0.000194672,0.000122544,0.0000268715,0.00003112686,0.0001297091],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1629985,"threshold_uncertainty_score":0.8539906,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01037364622421822,"score_gpt":0.2406844353598989,"score_spread":0.2303107891356807,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}